Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dasatinib + Quercetin (Senolytic Stack) | FOXO4-DRI | |
|---|---|---|
| Category | Pharmaceuticals | Peptides |
| Standard Dose | Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing). | Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly. |
| Timing | Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion. | No established timing protocol. |
| Cycle Duration | Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess). | Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.
Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).
Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.
Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).
FOXO4-DRI is a D-retro-inverso peptide that selectively targets the FOXO4-p53 protein-protein interaction in senescent cells. In senescence, FOXO4 binds p53's disordered transactivation domain (TAD2) in the nucleus, preventing p53 from translocating to mitochondria where it would trigger apoptosis. FOXO4-DRI competitively disrupts this interaction, causing nuclear exclusion of p53 and its redirection to mitochondria, selectively inducing apoptosis in senescent cells while sparing healthy cells. The D-retro-inverso configuration provides protease resistance.
Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly.
No established timing protocol.
Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →